Expert Interview
Discussing Morphic's MORF-057, an oral α4β7 integrin, for treatment in adults with moderate to severe ulcerative colitis
Ticker(s): MORFInstitution: GI Alliance
- Gastroenterologist at GI Alliance.
- Currently manages 100 patients with ulcerative colitis.
- Clinical interests include inflammatory bowel diseases and he has served as Site Principal Investigator for multiple phase I-IV clinical trials in Crohn’s disease and ulcerative colitis.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
